$NVCT News

Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know

Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

Nuvectis Pharma's Ciprocopan Receives Marketing Approval From National Medicinal Products Administration Of China To Treat Paroxysmal Nocturnal Hemoglobinuria

StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data

Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?

Roth Capital Maintains Buy on Nuvectis Pharma, Raises Price Target to $33

What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now?

Nuvectis: 'Hold' On NXP800 Removal And Newly Licensed Candidates

Nuvectis Pharma shares slide after pricing $100 million discounted stock offering (NVCT)

Reported Earlier, Nuvectis Pharma Prices $100M Public Offering Of 5M Common Shares At $20.00 Per Share

Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock

Nuvectis Pharma Announces Proposed Public Offering of Common Stock

Nuvectis Pharma Commences Common Stock Offering; Terms Undisclosed

What Makes Nuvectis Pharma (NVCT) a New Buy Stock

Haisco and Nuvectis sign licensing deal for two drugs

Haisco Enters into Exclusive License Agreement with Nuvectis for Two Drug Candidates in Oncology and Complement Indications

Nuvectis Pharma Jumps 20% To 52-Week High — Here's Why NVCT Stock Is Trending

Nuvectis Expands Pipeline with Haisco Licensing Agreement for Two Clinical-Stage Drug Candidates (NVCT)

HC Wainwright & Co. Maintains Buy on Nuvectis Pharma, Raises Price Target to $39

Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds